A physiologically based pharmacokinetic (PB-PK) model for CHCl 3 has been used to prepare estimates of the probability that human populations exposed to low levels of CHCl 3 will develop liver tumors similar to those seen in rodent bioassays. The PB-PK model for CHCl 3 was based on a model reported earlier by Corley et al. (1990), but this model differed from that of Corley et al. in that it was also capable of describing a pharmacodynamic endpoint: induction of cytotoxicity in the liver of CHCl 3-exposed animals produced by reactive metabolites of CHCl 3. Pharmacodynamic descriptions in this model were derived from experimental measurements of cell replication ([ 3H]thymidine incorporation) as well as from quantitative histopathology in the liver of rats and mice. Two different approaches were used for hazard evaluation: (1) a “Safety Factor” approach based on no observed effect levels for liver tumors, and (2) calculation of lower confidence limits on risk-specific doses with the GLOBAL83 computer program. In each case, cytotoxicity produced by reactive CHCl 3 metabolites was used as the measure of “dose” to the liver. The Safety Factor approach suggested that continuous exposure of human populations to concentrations of CHCl 3 less than 2840 ppb in air or 13,900 ppb in water would not be likely to significantly increase the risk of developing liver tumors. The second approach suggested a “plausible upper 95% confidence limit” of 1 × 10 −5 for lifetime excess cancer risk for human populations continuously exposed to 2200 or 13,100 ppb CHCl 3 in air or water, respectively.